Our target is to make our innovative medical devices spreading all over the world and provide better therapies for patients.
The molecular mechanisms of the LIPUS therapy include mechano-transduction mediated by β1-integrin/caveolin-1 with resultant upregulation of endothelial NO synthase(eNOs) and vascular endothelial growth factor(VEGF). It enhances angiogenesis in ischemic tissue and induces spontaneous improvement of microcirculatory disorder for both severe angina and mild dementia. Two pipelines are in clinical study.
Comparing to the ablation catheter that has been used for the treatment of arrhythmia, SWCS could treat deeper Arrhythmia source with less surface / peripheral tissues damage and less Thrombus formation.